3 results
Approved WMOCompleted
To investigate if sunitinib has clinical significant activity in patients with metastatic/recurrent paraganglioma/pheochromocytoma.
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMORecruiting
To study the effect of voxelotor on the hemodynamics of the cerebral vasculature (CBF and CVR)